Triple
T6251173
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | Regeneron Pharmaceuticals |
E140048
|
entity |
| Predicate | notableProduct |
P1448
|
FINISHED |
| Object | Dupixent |
E561777
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Dupixent | Statement: [Regeneron Pharmaceuticals, notableProduct, Dupixent]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Dupixent Context triple: [Regeneron Pharmaceuticals, notableProduct, Dupixent]
-
A.
Dupixent
chosen
Dupixent is a prescription biologic medication (dupilumab) used to treat moderate-to-severe inflammatory conditions such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps.
-
B.
Taltz
Taltz is a prescription biologic medication (ixekizumab) used to treat moderate to severe plaque psoriasis and certain types of arthritis by targeting the inflammatory protein IL-17A.
-
C.
Xolair
Xolair is a monoclonal antibody medication used to treat moderate to severe allergic asthma and chronic spontaneous urticaria by targeting immunoglobulin E (IgE).
-
D.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
E.
Xeljanz
Xeljanz is an oral Janus kinase (JAK) inhibitor medication used primarily to treat autoimmune conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69c008b4858c819095b0199114a9a87b |
completed | March 22, 2026, 3:20 p.m. |
| NER | Named-entity recognition | batch_69c0633fb2ac8190b71b8e35fa923300 |
completed | March 22, 2026, 9:46 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69c244240b448190be3645177194ced6 |
completed | March 24, 2026, 7:58 a.m. |
Created at: March 22, 2026, 4:24 p.m.